Diabetes, Metabolic Syndrome and Obesity (May 2020)
Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus
Abstract
Gebrehiwot Gebremedhin Tafere, Dawit Zewdu Wondafrash, Kaleab Alemayehu Zewdie, Brhane Teklebrhan Assefa, Muluken Altaye Ayza Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, EthiopiaCorrespondence: Gebrehiwot Gebremedhin TafereDepartment of Pharmacology and Toxicology,School of Pharmacy, Mekelle University, P.O. Box: 1871, Mekelle, EthiopiaTel +251 908822323Email [email protected]: Diabetes mellitus (DM) is a worldwide health threat affecting millions of people, which is associated with different micro- and macro-vascular complications. Type 2 diabetes mellitus (T2DM) is one of the different types of DM caused by insulin resistance and/or reduced secretion of insulin from the pancreas. A validated novel biomarker is required to enhance the accuracy of disease prediction, provide novel insights into pathophysiology and contribute to future prevention of T2DM. Various newer diagnostic methods have been developed by targeting endogenous proteins among which Adipsin is one of the promising target. Therefore, this review discusses Adipsin as a potential biomarker and its implication in T2DM. Adipsin is one of the adipokines secreted by adipose tissues which is involved in maintaining adipose tissue homeostasis and increasing insulin secretion in response to glucose. According to different experimental and clinical studies, plasma Adipsin concentrations are low in animals and patients with DM which support its use as a biomarker in combination to the other diagnostic modalities for DM. Additionally, the existence of Adipsin could be important in improving hyperglycemia by preserving β-cell mass through improving β-cell survival and maintaining their transcriptional identity.Keywords: adipsin, type 2 diabetes mellitus, biomarker
